Vaccine against herpes zoster (shingles, shingles) 3/5 (1)

Share Button

A new, non-live vaccine (Shingrix) on the European market, but not yet available on the Norwegian market (as per 2019). The vaccine should have about 90% protection and relatively little risk of side effects. Two injections are needed. The vaccine is then assumed to work for 10 years.

  • The current vaccine in Norway is Zostavax, which consists of live viruses
    • Vaccine against Herpes zoster can prevent about 50% of cases
    • Effect for at least 3 years
    • The vaccine is recommended for people over 50 years of age who are particularly susceptible to Herpes zoster
    • The vaccine consists of living (weakened) viruses
    • The content is essentially the same as in the vaccine against chickenpox, but in a higher dose
    • It is unusual for the vaccine to trigger Herpes zoster if it is given correctly (see contraindications below)

Contraindications (indicating that the vaccine should not be given)

Unlike the new vaccine (Shingrix), the "living" old vaccine (Zostavax) should not be given by impaired immune system because one can then get herpes zoster symptoms even by the weakened vaccine virus.

Literature


This page has had 3 visits today

Please rate this page